Press release
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical
To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Focal Segmental Glomerulosclerosis Market Forecast
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Focal Segmental Glomerulosclerosis Market Report:
• The Focal Segmental Glomerulosclerosis market size was valued approximately USD 300 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• More than 200,000 cases of focal segmental glomerulosclerosis (FSGS) were diagnosed in the 7MM population worldwide in 2021, with the US having the highest prevalence. Germany accounted for more than 23,000 cases in the EU5 nations in 2021.
• Japan had close to 35,000 cases in 2021, which accounted for approximately XX% of the total 7MM diagnosed prevalent cases of FSGS
• Key Focal Segmental Glomerulosclerosis Companies: Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others
• Key Focal Segmental Glomerulosclerosis Therapies: DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others
• The Focal Segmental Glomerulosclerosis epidemiology based on gender analyzed that Focal Segmental Glomerulosclerosis is more prevalent in males than females in the United States
• The Focal Segmental Glomerulosclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Focal Segmental Glomerulosclerosis pipeline products will significantly revolutionize the Focal Segmental Glomerulosclerosis market dynamics.
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a kidney disorder characterized by scarring (sclerosis) in the glomeruli, which are the tiny blood vessels in the kidneys responsible for filtering waste and excess fluid from the blood to form urine. In FSGS, scar tissue forms in some of the glomeruli, impairing their ability to function properly. This can lead to proteinuria (excessive protein in the urine), which may result in swelling (edema), high blood pressure, and impaired kidney function over time.
Get a Free sample for the Focal Segmental Glomerulosclerosis Market Report:
https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Focal Segmental Glomerulosclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Focal Segmental Glomerulosclerosis Epidemiology Segmentation:
The Focal Segmental Glomerulosclerosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Focal Segmental Glomerulosclerosis
• Prevalent Cases of Focal Segmental Glomerulosclerosis by severity
• Gender-specific Prevalence of Focal Segmental Glomerulosclerosis
• Diagnosed Cases of Episodic and Chronic Focal Segmental Glomerulosclerosis
Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis epidemiology trends @ Focal Segmental Glomerulosclerosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Focal Segmental Glomerulosclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Focal Segmental Glomerulosclerosis market or expected to get launched during the study period. The analysis covers Focal Segmental Glomerulosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Focal Segmental Glomerulosclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Focal Segmental Glomerulosclerosis Therapies and Key Companies
• Sparsentan: Travere Therapeutics
• DMX-200: Dimerix
• GFB-887: Goldfinch Bio
• VX-147: Vertex Pharmaceuticals
• Losmapimod: GlaxoSmithKline
• Propagermanium: Dimerix Bioscience Pty Ltd
• RE-021 (Sparsentan): Travere Therapeutics, Inc.
• CCX140-B: ChemoCentryx
• Dapagliflozin: AstraZeneca
• rituximab: Genentech, Inc.
• fresolimumab: Sanofi
• Acthar Gel: Mallinckrodt ARD LLC
• VB119: ACELYRIN Inc.
• Bleselumab: Kyowa Kirin Co., Ltd.
• Abatacept: Bristol-Myers Squibb
Discover more about therapies set to grab major Focal Segmental Glomerulosclerosis market share @ Focal Segmental Glomerulosclerosis Treatment Market
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Focal Segmental Glomerulosclerosis Market Strengths
• The frequency of Focal Segmental Glomerulosclerosis appears to be increasing worldwide, which presents a promising opportunity for various companies to develop novel therapies
• The advent of next-generation sequencing promises to provide nephrologists with rapid and novel approaches for diagnosing and treating Focal Segmental Glomerulosclerosis
• A stratified and targeted approach is being evolved based on the underlying molecular defects
Focal Segmental Glomerulosclerosis Market Unmet Needs
• Heterogeneity in the disease presentation
• The requirement for cutting-edge diagnosis
• Restricted specific epidemiological studies
• Inadequate therapeutic options
Scope of the Focal Segmental Glomerulosclerosis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Focal Segmental Glomerulosclerosis Companies: Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others
• Key Focal Segmental Glomerulosclerosis Therapies: DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others
• Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
• Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Focal Segmental Glomerulosclerosis Unmet Needs, KOL's views, Analyst's views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement
To know more about Focal Segmental Glomerulosclerosis companies working in the treatment market, visit @ Focal Segmental Glomerulosclerosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Focal Segmental Glomerulosclerosis Market Report Introduction
2. Executive Summary for Focal Segmental Glomerulosclerosis
3. SWOT analysis of Focal Segmental Glomerulosclerosis
4. Focal Segmental Glomerulosclerosis Patient Share (%) Overview at a Glance
5. Focal Segmental Glomerulosclerosis Market Overview at a Glance
6. Focal Segmental Glomerulosclerosis Disease Background and Overview
7. Focal Segmental Glomerulosclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Focal Segmental Glomerulosclerosis
9. Focal Segmental Glomerulosclerosis Current Treatment and Medical Practices
10. Focal Segmental Glomerulosclerosis Unmet Needs
11. Focal Segmental Glomerulosclerosis Emerging Therapies
12. Focal Segmental Glomerulosclerosis Market Outlook
13. Country-Wise Focal Segmental Glomerulosclerosis Market Analysis (2019-2032)
14. Focal Segmental Glomerulosclerosis Market Access and Reimbursement of Therapies
15. Focal Segmental Glomerulosclerosis Market Drivers
16. Focal Segmental Glomerulosclerosis Market Barriers
17. Focal Segmental Glomerulosclerosis Appendix
18. Focal Segmental Glomerulosclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Focal Segmental Glomerulosclerosis Pipeline https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Focal Segmental Glomerulosclerosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Focal Segmental Glomerulosclerosis market. A detailed picture of the Focal Segmental Glomerulosclerosis pipeline landscape is provided, which includes the disease overview and Focal Segmental Glomerulosclerosis treatment guidelines.
Focal Segmental Glomerulosclerosis Epidemiology https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Focal Segmental Glomerulosclerosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Focal Segmental Glomerulosclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Cancer Diagnostics Market
https://www.delveinsight.com/report-store/cancer-diagnostic-market
Cancer Diagnostics Market By Type (Product Type [Reagent & Kits and Instruments], and Services), Technique (Molecular Diagnostics [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, and Immunohistochemistry], Diagnostics Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, and Nuclear Medicine Scans], Endoscopy, and Biopsy [Standard Biopsy and Liquid Biopsy]), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others), End-User (Hospitals, Diagnostics Labs, and Others), and Geography, is expected to grow at a significant CAGR forecast till 2028 owing to the growing burden of cancer across the globe and rise in various product launches for efficient detection of cancer.
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to lauch of advanced devices and increasing prevalence of respiratory diseases such as COPD.
Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.
Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical here
News-ID: 3466260 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Focal
Focal Epilepsy Market New Product Development & Latest Trends
Introduction
Focal epilepsy, the most common form of epilepsy worldwide, originates in specific regions of the brain and often presents with partial seizures. Affecting millions of people globally, focal epilepsy remains a pressing neurological challenge with significant clinical and economic impact. Increasing diagnosis rates, technological advances in imaging and neurostimulation, and new pharmacological approaches are fueling rapid changes in the treatment landscape.
As healthcare systems place greater emphasis on effective long-term management…
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $22.41 billion In…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
